Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter of 2021, and provided updates on its strong ophthalmology pipeline. “Our progress in the first quarter of 2021 was significant,” said Antony Mattessich, President and Chief Executive Officer. “Revenue for DEXTENZA® w